DYADIC INTERNATIONAL INC (DYAI) Operating Margin
- Operating margin · 12 months: Value -195.10%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -195.10% | Operating income / revenue. Period ending 2026-06-30. $-7.42M ÷ $3.80M × 100 ≈ -195.10% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -7.42M USD | Operating Income (Loss) |
| Revenue | 3.80M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 3.18M USD | Cost of Goods and Services Sold |
| Research and development | 1.84M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-7.42M | $3.80M | $3.18M | $1.84M | (m) | -195.10% |
| 2026-03-31 | $-7.09M | $3.81M | $2.81M | $2.14M | (m) | -186.28% |
| 2025-12-31 | $-7.19M | $3.09M | $2.32M | $2.15M | (m) | -232.75% |
| 2025-09-30 | $-7.19M | $3.34M | $2.29M | $2.24M | (m) | -215.04% |
| 2025-06-30 | $-5.46M | $4.14M | (m) | $2.13M | (m) | -132.14% |
| 2025-03-31 | $-5.78M | $3.55M | (m) | $2.02M | (m) | -162.55% |
| 2024-12-31 | $-5.90M | $3.50M | $1.19M | $2.04M | (m) | -168.82% |
| 2024-09-30 | $-6.54M | $3.36M | $1.19M | $2.35M | (m) | -194.36% |
| 2024-06-30 | $-8.06M | $1.80M | $901.90K | $2.61M | (m) | -446.59% |
| 2024-03-31 | $-8.30M | $2.26M | $1.39M | $3.01M | (m) | -368.22% |
| 2023-12-31 | $-8.23M | $2.90M | $1.98M | $3.30M | (m) | -283.90% |
| 2023-09-30 | $-8.30M | $2.96M | $2.33M | $3.03M | (m) | -280.81% |
| 2023-06-30 | $-8.44M | $3.44M | $2.83M | $3.06M | (m) | -245.57% |
| 2023-03-31 | $-9.47M | $3.26M | $2.45M | $3.97M | (m) | -290.54% |
| 2022-12-31 | $-10.17M | $2.93M | $2.12M | $4.50M | (m) | -346.92% |
| 2022-09-30 | $-12.14M | $2.50M | $1.75M | $6.39M | (m) | -485.70% |
| 2022-06-30 | $-13.60M | $2.31M | $1.54M | $7.55M | (m) | -588.04% |
| 2022-03-31 | $561.26M | $190.31M | $15.93M | $-456.84M | (m) | 294.92% |
| 2021-12-31 | $-14.73M | $2.40M | $1.94M | $8.39M | (m) | -612.67% |
| 2021-09-30 | $-12.78M | $2.44M | $1.87M | $6.93M | (m) | -524.55% |
| 2021-06-30 | $-12.03M | $2.16M | $1.74M | $6.01M | (m) | -557.10% |
| 2021-03-31 | $-10.96M | $1.75M | $1.54M | $4.92M | (m) | -627.55% |
| 2020-12-31 | $-10.03M | $1.60M | $1.42M | $3.87M | (m) | -625.85% |
| 2020-09-30 | $-9.69M | $1.69M | $1.59M | $3.59M | (m) | -573.84% |
| 2020-06-30 | $-9.06M | $1.73M | $1.71M | $3.45M | (m) | -524.53% |
| 2020-03-31 | $-9.22M | $1.59M | $1.41M | $3.15M | (m) | -578.69% |
| 2019-12-31 | $-9.28M | $1.68M | $1.46M | $3.09M | (m) | -552.18% |
| 2019-09-30 | $-9.11M | $1.93M | $1.54M | $2.80M | (m) | -470.94% |
| 2019-06-30 | $-8.95M | $1.74M | $1.40M | $2.43M | (m) | -513.37% |
| 2019-03-31 | $-7.80M | $1.51M | $1.21M | $2.22M | (m) | -515.58% |
| 2018-12-31 | $-7.59M | $1.30M | $1.03M | $2.10M | (m) | -586.09% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-7.13M | $758.42K | $680.20K | $1.77M | (m) | -939.70% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |